MedTrace Logo

Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer

NCT02483104 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2017-11-20

No results posted yet for this study

Summary

This is a Phase 1, open-label, multicenter, dose escalation study evaluating the tolerability, safety, pharmacokinetics and preliminary efficacy of veliparib in combination with carboplatin and weekly paclitaxel in Japanese subjects with ovarian cancer.

Conditions

Interventions

DRUG

veliparib

Veliparib will be given orally, twice daily on Days 1-21, every 21 days.

DRUG

carboplatin

Carboplatin will be administered on Day 1 of each cycle, intravenously.

DRUG

paclitaxel

Paclitaxel will be administered on Days 1, 8, 15 of each cycle, intravenously.

Sponsors & Collaborators

Principal Investigators

  • Hideyuki Hashiba, BS · AbbVie

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
99 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2016-03-31
Completion
2016-07-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02483104 on ClinicalTrials.gov